Skip to contentISALY SAMUEL D — INTERCEPT PHARMACEUTICALS INC insider: 234 transactions · InsiderLensISALY SAMUEL D
- Director at DOV PHARMACEUTICAL INC · on record since May 18, 2006
- Director at AVANIR PHARMACEUTICALS · on record since Feb 23, 2006
- Director at GIVEN IMAGING LTD · on record since May 26, 2006
- 10% owner at GIVEN IMAGING LTD · on record since May 26, 2006
- Director at Volcano CORP · on record since Jun 20, 2006
- Director at MEMORY PHARMACEUTICALS CORP · on record since Apr 7, 2004
- FN4 at MEMORY PHARMACEUTICALS CORP · on record since Apr 7, 2004
- Director at ARYx Therapeutics, Inc. · on record since Nov 15, 2007
- 10% owner at SteadyMed Ltd. · on record since Aug 12, 2016
- 10% owner at CRYOCOR INC · on record since Jun 19, 2007
- Director at INSULET CORP · on record since May 14, 2007
- Director at Loxo Oncology, Inc. · on record since Aug 12, 2016
- Director at Biodel Inc · on record since Feb 14, 2008
- 10% owner at Biodel Inc · on record since Feb 14, 2008
- 10% owner at NxStage Medical, Inc. · on record since May 30, 2008
- Director at BTHC VI Inc · on record since May 23, 2008
- 10% owner at BTHC VI Inc · on record since May 23, 2008
- Director at NxStage Medical, Inc. · on record since Aug 28, 2008
- 10% owner at ARYx Therapeutics, Inc. · on record since Nov 18, 2008
- 10% owner at INSITUFORM TECHNOLOGIES INC · on record since May 17, 2004
- 10% owner at Relypsa Inc · on record since Nov 20, 2013
- 10% owner at Aspen Racing Stables. Inc. · on record since May 10, 2010
- 10% owner at COMPLETE GENOMICS INC · on record since Nov 10, 2010
- 10% owner at Anthera Pharmaceuticals Inc · on record since Oct 4, 2010
- Director at AMARIN CORP PLC · on record since Mar 28, 2011
- 10% owner at Pacira Pharmaceuticals, Inc. · on record since Feb 10, 2011
- 10% owner at AMARIN CORP PLC · on record since Jan 3, 2011
- Director at Anthera Pharmaceuticals Inc · on record since May 27, 2011
- 10% owner at ChemoCentryx, Inc. · on record since Feb 15, 2012
- 10% owner at RESPONSE BIOMEDICAL CORP · on record since Jan 11, 2012
- Director at Nabriva Therapeutics AG · on record since Dec 30, 2016
- 10% owner at Nabriva Therapeutics AG · on record since Dec 30, 2016
- 10% owner at SUPERNUS PHARMACEUTICALS INC · on record since Apr 30, 2012
- Director at SUPERNUS PHARMACEUTICALS INC · on record since May 8, 2012
- 10% owner at INTERCEPT PHARMACEUTICALS INC · on record since Oct 16, 2012
- 10% owner at LIFECELL CORP · on record since Dec 30, 2003
- 10% owner at AMBIT BIOSCIENCES CORP · on record since May 24, 2013
- Director at INTERCEPT PHARMACEUTICALS INC · on record since Apr 15, 2013
- Former 10% Owner at ACCELERON PHARMA INC · on record since Sep 26, 2013
- 10% owner at ACCELERON PHARMA INC · on record since Sep 18, 2013
- 10% owner at Mirati Therapeutics, Inc. · on record since Jul 16, 2013
- 10% owner at Loxo Oncology, Inc. · on record since Jul 31, 2014
- 10% owner at Roka BioScience, Inc. · on record since Jul 24, 2014
- 10% owner at Otonomy, Inc. · on record since Aug 19, 2014
- 10% owner at NETWORK INSTALLATION CORP · on record since Oct 28, 2014
- Director at GLAUKOS Corp · on record since Jun 30, 2015
- 10% owner at GLAUKOS Corp · on record since Jun 30, 2015
- Director at PALVELLA THERAPEUTICS, INC. · on record since Jun 29, 2015
- 10% owner at PALVELLA THERAPEUTICS, INC. · on record since Jun 29, 2015
- Director at ProNAi Therapeutics Inc · on record since Jul 21, 2015
- Director at Otonomy, Inc. · on record since Nov 30, 2015
- Director at Dimension Therapeutics, Inc. · on record since Oct 29, 2015
- 10% owner at Dimension Therapeutics, Inc. · on record since Oct 29, 2015
- 10% owner at ViewRay, Inc. · on record since Mar 30, 2016
- Director at Adaptimmune Therapeutics PLC · on record since Jan 4, 2016
- Director at Cartesian Therapeutics, Inc. · on record since Jun 29, 2016
- 10% owner at Cartesian Therapeutics, Inc. · on record since Jun 29, 2016
- Director at Corvus Pharmaceuticals, Inc. · on record since Jun 27, 2016
- 10% owner at Corvus Pharmaceuticals, Inc. · on record since Jun 27, 2016
- Director at RESPONSE BIOMEDICAL CORP · on record since Jun 20, 2016
- 10% owner at Spyre Therapeutics, Inc. · on record since Apr 19, 2016
- Director at Intellia Therapeutics, Inc. · on record since May 13, 2016
- 10% owner at Intellia Therapeutics, Inc. · on record since May 5, 2016
- Director at ViewRay, Inc. · on record since Aug 24, 2016
- Director at Roka BioScience, Inc. · on record since Sep 23, 2016
- Director at BOLD ENERGY INC. · on record since Jul 19, 2016
- 10% owner at BOLD ENERGY INC. · on record since Jul 19, 2016
- Director at ZETA ACQUISITION CORP II · on record since Mar 17, 2017
- 10% owner at ZETA ACQUISITION CORP II · on record since Mar 17, 2017
- 10% owner at CELL THERAPEUTICS INC · on record since Jun 15, 2017
- Director at Mirna Therapeutics, Inc. · on record since Aug 30, 2017
- Director at ALPINE AIR EXPRESS INC/DE · on record since Jul 26, 2017
- 10% owner at ALPINE AIR EXPRESS INC/DE · on record since Jul 26, 2017
- 10% owner at Kala Pharmaceuticals, Inc. · on record since Jul 19, 2017
- 10% owner at scPharmaceuticals Inc. · on record since Nov 21, 2017
- 10% owner at ACTELIS NETWORKS INC · on record since Nov 20, 2017
- 10% owner at RHYTHM PHARMACEUTICALS, INC. · on record since Oct 10, 2017
- 10% owner at XTENT INC · on record since Jan 19, 2018
- Director at ORPHAN MEDICAL INC · on record since May 6, 2005
- Director at CRYOCOR INC · on record since Jul 18, 2005
Insider trading activity of ISALY SAMUEL D
- Transactions on record
- 234
- since Dec 30, 2003
- Open-market buys
- 34
- $54.5M
- Open-market sells
- 147
- $430.9M
- Companies traded
- 30
- last filing Jan 4, 2018
Figures computed from official regulatory filings — methodology.
Companies where ISALY SAMUEL D has traded
- PALVELLA THERAPEUTICS, INC.4 tx · $13.9M · Jan 4, 2018
- Loxo Oncology, Inc.5 tx · $20.1M · Nov 20, 2017
- RHYTHM PHARMACEUTICALS, INC.3 tx · $6M · Oct 10, 2017
- BOLD ENERGY INC.1 tx · $19M · Sep 29, 2017
- Roka BioScience, Inc.4 tx · $125.6K · Sep 28, 2017
- GLAUKOS Corp12 tx · $25.1M · Sep 5, 2017
- Kala Pharmaceuticals, Inc.3 tx · $4.8M · Jul 27, 2017
- CELL THERAPEUTICS INC2 tx · Jun 15, 2017
- Adaptimmune Therapeutics PLC1 tx · $5M · Mar 28, 2017
Track record of ISALY SAMUEL D
Statistical track record
Free- Open-market buys
- 40
- Last buy
- Oct 10, 2017
Win rates and median returns are available with a free account (5 insiders/month).
Create a free account→Transaction history of ISALY SAMUEL D
Co-insiders of ISALY SAMUEL D
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
1 tx · $3.8M · Mar 17, 2017
Viswanathan RaviACTELIS NETWORKS INC +5
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Jan 4, 2018 | Sell | -1,693,492 | 7.35 USD | $12.4M | SEC |
| Jan 4, 2018 | Sell | -16,128 | 7.35 USD | $118.5K | SEC |
| Nov 20, 2017 | Sell | -43,300 | 73.48 USD | $3.2M | SEC |
| Nov 20, 2017 | Sell | -46,680 | 72.46 USD | $3.4M | SEC |
| Nov 20, 2017 | Sell | -100,045 | 74.49 USD | $7.5M | SEC |
| Nov 20, 2017 | Sell | -8,377 | 76.23 USD | $638.6K | SEC |
| Nov 20, 2017 | Sell | -71,598 | 75.37 USD | $5.4M | SEC |
| Oct 10, 2017 | Other | 2,546,295 | — | — | SEC |
| Oct 10, 2017 | OtherD | -2,546,295 | 0.00 USD | $0 | SEC |
| Oct 10, 2017 | Buy | 355,000 | 17.00 USD | $6M | SEC |
| Sep 29, 2017 | Sell | -672,000 | 28.25 USD | $19M | SEC |
| Sep 28, 2017 | Sell | -706 | 1.03 USD | $727.2 | SEC |
| Sep 28, 2017 | Sell | -498 | 0.92 USD | $458.2 | SEC |
| Sep 28, 2017 | Sell | -52,301 | 0.92 USD | $48.1K | SEC |
| Sep 28, 2017 | Sell | -74,096 | 1.03 USD | $76.3K | SEC |
| Sep 5, 2017 | Sell | -189,792 | 39.63 USD | $7.5M | SEC |
| Sep 5, 2017 | Sell | -424 | 37.82 USD | $16K | SEC |
| Sep 5, 2017 | Sell | -58,047 | 40.77 USD | $2.4M | SEC |
| Sep 5, 2017 | Sell | -109,040 | 37.72 USD | $4.1M | SEC |
| Sep 5, 2017 | Sell | -173,349 | 37.94 USD | $6.6M | SEC |
| Sep 5, 2017 | Sell | -44,498 | 37.82 USD | $1.7M | SEC |
| Sep 5, 2017 | Sell | -553 | 40.77 USD | $22.5K | SEC |
| Sep 5, 2017 | Sell | -1,038 | 37.72 USD | $39.2K | SEC |
| Sep 5, 2017 | Sell | -1,808 | 39.63 USD | $71.7K | SEC |
| Sep 5, 2017 | Sell | -1,651 | 37.94 USD | $62.6K | SEC |